Picture of Swedish Orphan Biovitrum AB (publ) logo

SOBI — Swedish Orphan Biovitrum AB (publ) News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Earnings Poll: Swedish Orphan Biovitrum fourth quarter results due on February 5

Feb 4 (Reuters) - (All figures in Swedish Crowns)
    * Swedish Orphan Biovitrum AB (publ)  SOBIV.ST  reports
its fourth
quarter results on February 5. 
    * Year to date, Swedish Orphan Biovitrum AB (publ) shares
are up
5.80%.
    * Below is a table of quarterly and annual analyst estimates
for
results based on LSEG data.

 Qtr. to      No. of       Mean
 December     analysts     Estimate
 2024                      
 Revenue      7            7.38
                           billion
 Pre-tax      4            1.47
 profit                    billion
 EPS          4            3.51
 EBITDA       4            2.62
                           billion
 EBIT         6            1.84
                           billion
 Net Profit   5            1.20
                           billion
 
 Year to       No. of        Mean
 December      Analysts      Estimate
 2024                        
 Revenue       13            25.87
                             billion
 Pre-tax                     
 profit        8             4.42 billion
                             
 EPS                         
               11            10.97
                             
 EBITDA                      
               12            9.48 billion
                             
 EBIT                        
               10            5.81 billion
                             
 Net Profit    10            3.73 billion
 Dividend      9             0.00
 Net Debt      7             13.77
                             billion
 
Swedish Orphan Biovitrum AB (publ) belongs to the OMX
Stockholm_PI. Please note that consensus estimates may be
updated between publication of the poll and the report.
This summary was auto generated on February 3 at 07:17.

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Swedish Orphan Biovitrum AB (publ)

See all news